PROTEASE INHIBITORS AND PENETRATION ENHANCERS AS APPROACHES TO MODIFY PEPTIDE ABSORPTION

被引:84
作者
LEE, VHL
机构
[1] University of South California, School of Pharmacy, Los Angeles, CA 90033
关键词
paracellular pathway; penetration enhancers; peptidase inhibitors; peptide delivery systems; transmucosal peptide absorption;
D O I
10.1016/0168-3659(90)90011-H
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The proteolytic and penetration barriers are formidable barriers that must be overcome in considering any non-parenteral route of peptide and protein drug delivery. While chemical modification of the primary structure has been successful in protecting peptides from proteolysis, this is not so in the case of proteins because of their structural complexity. Consequently, the use of protease inhibitors must be considered. The selection of protease inhibitors depends on the principal proteases mediating the degradation of a given peptide or protein, their subcellular compartmentalization, their ability to reach the target and the mechanisms by which the peptide or protein crosses the mucosal epithelial layer. In addition to protease inhibitors, penetration enhancers are also required. Penetration enhancers act by diverse mechanisms, including fluidization of the plasma membrane, loosening of the tight junctions between cells, inhibition of proteases and increasing the thermodynamic activity of proteins prone to self-association. Before protease inhibitors and penetration enhancers can be used on a routine basis, however, their short- and long-term effects on the well-being of the mucosal cells and the rest of the body must be ascertained. This paper will review the experience with protease inhibitors and penetration enhancers to date, address the concerns with their routine use and examine some alternative approaches to promote mucosal peptide and protein absorption. © 1990.
引用
收藏
页码:213 / 223
页数:11
相关论文
共 109 条
  • [1] Okada, Yamazaki, Ogawa, Hirai, Yashiki, Mima, Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats. I. Absorption by various routes and absorption enhancement, J. Pharm. Sci., 71, pp. 1367-1371, (1982)
  • [2] Okada, Yamazaki, Yashiki, Mima, Vaginal absorption of a potent luteinizing hormonereleasing hormone analogue (leuprolide) in rats. II. Mechanism of absorption enhancement with organic acids, J. Pharm. Sci., 72, pp. 75-78, (1983)
  • [3] Danforth, Moore, Intestinal absorption of insulin in the rat, Endocrinology, 65, pp. 118-123, (1959)
  • [4] Redding, Schally, A study on the mode of administration of thyrotropin releasing hormone (TRH) in mice, Neuroendocrinology, 6, pp. 329-335, (1970)
  • [5] Berger, Halban, Girardier, Seydoux, Offord, Renold, Absorption kinetics of subcutaneously injected insulin. Evidence for degradation at injection site, Diabetologia, 17, pp. 97-99, (1979)
  • [6] Lauritzen, Faber, Binder, Variation in <sup>125</sup>I-insulin absorption and blood glucose concentration, Diabetologia, 17, pp. 291-295, (1979)
  • [7] Paulsen, Courtney, Duckworth, Accelerated insulin degradation: an alternative mechanism for insulin resistance, Diabetes Care, 2, pp. 414-418, (1979)
  • [8] Freidenberg, White, Cataland, O'Dorisio, Sotos, Santiago, Diabetes responsive to intravenous but not subcutaneous insulin: effectiveness of aprotinin, N. Engl. J. Med., 305, pp. 363-368, (1981)
  • [9] Misbin, Almira, Cleman, Insulin degradation in the serum of a patient with apparent insulin resistance, J. Clin. Endocrinol. Metab., 52, pp. 177-180, (1981)
  • [10] Maberly, Wait, Kilpatrick, Loten, Gain, Stewart, Eastman, Evidence for insulin degradation by muscle and at tissue in an insulin resistant diabetic patient, Diabetologia, 23, pp. 333-336, (1982)